May 18, 2021
Multinational Patient Study Demonstrates Prevencio’s AI-driven HART Blood Test Highly Accurate for Risk of Heart Attack, Stroke, and Cardiac Death
Novel multi-protein blood test data on more than 1,500 patients presented at 2021 American College of Cardiology Scientific Sessions
KIRKLAND, WA — Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven blood test is more accurate than commonly-used risk factors, genetic tests, and coronary artery calcium scores in determining whether a person will have a heart attack or major cardiac event within the next year. Cardiologists believe the validation data, presented at this week’s American College of Cardiology (ACC) Scientific Sessions, could lead to significantly improved risk classification of patients, allowing for more aggressive therapy in higher-risk patients and avoiding expensive or invasive treatment in lower-risk patients.
May 4, 2021
Prevencio and Seattle Children’s Research Institute Present Highly Accurate Data for First Time Artificial Intelligence-driven
Multiple Protein Blood Test for Kawasaki Disease
Kawasaki Disease—a critical childhood disease—linked to COVID-19
KIRKLAND, WA — Prevencio, Inc. today announces presentation of highly accurate data on an Artificial Intelligence (AI)-driven blood test for Kawasaki disease (KD) at the Pediatric Academic Societies (PAS) International Sessions. The novel test, HART KD, was jointly developed with Seattle Children’s Research Institute and leveraged Prevencio’s AI-driven HART platform and expertise in developing cardiac blood tests. For the first time, KD can be accurately diagnosed with easily measured, multiple proteins in children’s blood. A key differentiator is using an AI-driven algorithm, or weighting of each protein, to enhance the accuracy to an impressive 92% (AUC), as compared to nonspecific, single protein tests. This provides a long-needed, diagnostic blood test to distinguish KD from other infectious and inflammatory conditions.
April 21, 2021
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
Commercial Launch Follows Successful Beta Testing of Prevencio’s Highly Accurate AI-driven HART Tests.
KIRKLAND, WA — Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are not disclosed.